Overview
Perimeter Medical Imaging AI, Inc. is a Canadian medical technology company that operates primarily in the healthcare sector, focusing on advanced imaging tools and artificial intelligence applications aimed at aiding cancer surgeries. The company's flagship project involves the development and commercialization of its Optical Coherence Tomography (OCT) imaging system, designed to provide real-time, high-resolution intraoperative scans of excised tissues. This allows for immediate assessment during cancer surgeries, potentially minimizing the rates of re-operation. By integrating AI technology, Perimeter Medical seeks to enhance the accuracy and efficiency of diagnoses directly in the surgical suite, thereby improving outcomes for patients while reducing costs for healthcare systems.
AI+ Ask Fintel’s AI assistant about Perimeter Medical Imaging AI, Inc..
Thinking about good questions…
Basic Stats
The share price of Perimeter Medical Imaging AI, Inc. as of June 10, 2024 is $0.34 / share. The market cap (or net worth) of Perimeter Medical Imaging AI, Inc. as of September 5, 2025 is $35.34 MM.
The Factor Analysis chart (below right) shows a view of Perimeter Medical Imaging AI, Inc. from a variety of lenses. Each factor shows how well the company ranks against all other companies in the Fintel global investing universe. Factor scores range from zero to 100, with 100 being most desirable, and 50 being average.
For example, a company with a Value Score of 100 would be the most undervalued company in our database. A company with a Value Score of zero would be the most overvalued.
| Market Cap | 35.34 MM |
| EV | 33.98 MM |
| Shares Out. | 103.95 MM |
| Earnings Date | |
| EPS (TTM) | -0.16 |
| Dividend Yield | |
| Ex-Dividend Date | |
| Borrow Rate | 12.39 |
| Short Shares Avail. | 0.04 MM |
| Short Interest | |
| Short Float | |
| Days to Cover | |
| Risk Free Rate | 4.17 % |
| Price Change (1 yr) | |
| Volatility (1 yr) | |
| Beta | |
| Sharpe Ratio (1 yr) | |
| Sortino Ratio (1 yr) |
| PE Ratio | -2.17 |
| Price/Book | 7.84 |
| Price/TBV | 7.84 |
| Book/Market | 0.13 |
| EBIT/EV | -0.48 |
| EBIT(3yr avg)/EV | -0.39 |
| ROA | -1.28 |
| ROE | -1.67 |
| ROIC | -3.53 |
| CROIC | -1.11 |
| OCROIC | -3.00 |
| Implied Volatility | |
| Put/Call OI Ratio |
Factor Scores range from 0 to 100, with 100 being most desirable. Larger circles are better. In situations where we have no data (e.g. no insider trades), we plot the score at 50 to avoid penalizing companies. However, a company that does not pay dividends will get a Dividend Score of Zero. Additionally, we inverted volatility to create a "stability" metric which is better when higher.
Price Target
The average one-year price target for Perimeter Medical Imaging AI, Inc. is $1.29. The forecasts range from a low of $0.69 to a high of $2.17. A stock’s price target is the price at which analysts consider it fairly valued with respect to its projected earnings and historical earnings. Analysts typically set price targets that correspond to their buy or sell recommendations.
Update Frequency: Monthly
Stock Upgrades/Downgrades
This card shows analyst upgrades/downgrades for Perimeter Medical Imaging AI, Inc.. An analyst rating is a classification that gives investors a sense of analyst sentiment about the direction and performance of an equity - usually a stock - over a period of time, typically 12 months.
The standard analyst ratings are generally as follows:
- Buy/Overweight/Outperform - Any of these ratings conveys an analyst’s belief that the stock is likely to outperform a market index (e.g. the S&P 500).
- Hold/Equal-Weight/Market Perform - Any of these ratings conveys an analyst’s belief that the stock is likely to perform in line with a market index.
- Sell/Underweight/Underperform - Any of these ratings suggest that an analyst believes the stock is likely to underperform a market index.
When an analyst upgrades a stock, they are signaling that the company’s fundamentals are being undervalued by investors. It could also mean they believe the market is underestimating the company’s potential. The opposite is true when a stock receives a downgrade.
The average rating of each individual analyst’s rating is the consensus rating for a stock. This gives investors a broader sense of the overall sentiment for that stock.
| Date | Analyst | Prior | Latest Recommendation |
Action |
|---|---|---|---|---|
| 2023-11-10 | LEEDE JONES GABLE | Buy | Buy | Maintains |
| 2023-08-31 | PARADIGM CAPITAL | Buy | Buy | Maintains |
| 2023-08-17 | LEEDE JONES GABLE | Buy | Buy | Maintains |
| 2023-08-16 | LEEDE JONES GABLE | Buy | Buy | Maintains |
| 2023-05-28 | PARADIGM CAPITAL | Buy | Buy | Maintains |
| 2023-05-27 | PARADIGM CAPITAL | Buy | Buy | Maintains |
| 2023-05-19 | LEEDE JONES GABLE | Buy | Buy | Maintains |
| 2023-05-18 | LEEDE JONES GABLE | Buy | Buy | Maintains |
| 2023-04-12 | LAKE STREET CAPITAL MARKETS | Buy | Buy | Maintains |
| 2023-04-11 | LAKE STREET CAPITAL MARKETS | Buy | Buy | Maintains |
| 2022-11-16 | LEEDE JONES GABLE | Buy | Buy | Maintains |
| 2022-11-16 | PARADIGM CAPITAL | Buy | Buy | Maintains |
| 2022-08-29 | RAYMOND JAMES LTD. | Outperform | Outperform | Maintains |
| 2022-08-28 | RAYMOND JAMES LTD. | Outperform | Outperform | Maintains |
| 2022-06-02 | RESEARCH CAPITAL CORPORATION | Buy | Buy | Maintains |
| 2022-06-01 | RESEARCH CAPITAL CORPORATION | Buy | Buy | Maintains |
| 2022-05-10 | Raymond James Capital | Outperform | Initiate | |
| 2021-12-16 | Raymond James Financial | Outperform | Initiate | |
| 2021-11-03 | RJ Financial | Outperform | Initiate | |
| 2021-09-02 | RESEARCH CAPITAL CORPORATION | Buy | Buy | Maintains |
| 2021-09-01 | RESEARCH CAPITAL CORPORATION | Buy | Buy | Maintains |
| 2021-05-17 | Raymond James Financial | Outperform | Initiate | |
| 2021-04-16 | Raymond James Financial | Outperform | Initiate | |
| 2021-04-15 | Raymond James Financial | Outperform | Initiate | |
| 2021-03-05 | Raymond James Financial | Outperform | Initiate | |
| 2024-03-27 | LEEDE JONES GABLE | Buy | Buy | Maintains |
| 2023-11-09 | LEEDE JONES GABLE | Buy | Buy | Maintains |
| 2023-08-30 | PARADIGM CAPITAL | Buy | Buy | Maintains |
| 2024-11-21 | PARADIGM CAPITAL | Buy | Buy | Maintains |
| 2024-11-20 | LEEDE JONES GABLE | Buy | Buy | Maintains |
| 2024-11-19 | RAYMOND JAMES LTD. | Outperform | Outperform | Maintains |
| 2025-05-13 | PARADIGM CAPITAL | Buy | Buy | Maintains |
| 2025-05-04 | LEEDE JONES GABLE | Buy | Buy | Maintains |
